# A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

> **NCT02179918** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 23 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** PF-05082566
- **DRUG:** MK-3475

## Key facts

- **NCT ID:** NCT02179918
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02179918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02179918, "A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02179918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*